Distinguished Lecture Series

Roswell Park Comprehensive Cancer Center is pleased to announce the establishment of a Distinguished Lecture Series, sponsored by Cancer Center Director, Dr. Candace Johnson.

Representatives from all research departments and divisions (clinical and basic) have identified top-level speakers known for their groundbreaking research in each of their fields, including many who are Directors of Cancer Centers in their own right. In addition to their giving a 50-minute lecture on their research aimed at audiences that include students, medical fellows, basic and clinical researchers, invited distinguished speakers will meet with students, fellows, and faculty members to learn about and discuss the exciting ongoing research projects at Roswell Park.

All upcoming lectures will be hosted at Roswell Park Comprehensive Cancer Center 
Gaylord Cary Conference Room, Research Studies Center
665 Elm Street (at the corner of Carlton & Elm Streets)

Buffalo, NY, 14263.

For additional details, please contact Amy Troutman at 716-845-3851 or Amy.Troutman@RoswellPark.org

Upcoming Lectures:

Jinghui Zhang, PhD, St. Jude, Distinguished Lecture Series 2023
Chair, Department of Computational Biology
Endowed Chair of Bioinformatics
St. Jude Children's Research Hospital
Memphis, Tennessee
Therapy-related clonal evolution in pediatric cancer patients and clonal hematopoiesis long-term survivors

Understanding the short-term and long-term therapy-related effect on the genomes of pediatric cancer and survivors is essential for reducing the mortality associated with cancer relapse and the accelerated physiological aging of long-term survivors. We present the discovery of therapy-related mutagenesis processes, including those involved in structural variations (SVs) in relapsed pediatric acute lymphoblastic leukemias and metastatic osteosarcoma, which give rise to resistant clones under the selective pressure of exposure to cytotoxic agents. We also present the dynamics of age- versus therapy-related clonal hematopoiesis (CH) in long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH-gene specific to Hodgkin lymphoma survivors, and TP53. Single-cell profiling of peripheral blood samples revealed STAT3 mutations predominantly present in T-cells and contributed by SBS25, a mutational signature associated with procarbazine exposure. Serial-sample tracking reveals that larger clone size is a predictor for future expansion of age-related CH clones, while therapy-related CH remains stable decades post-treatment. These data depict the distinct dynamics of these CH subtypes and support the need for longitudinal monitoring to determine the potential contribution to late effects.

Thursday, May 11, 2023, 3:00 p.m.

This lecture will be held at Roswell Park Comprehensive Cancer Center in the:

Zebro Family Conference Room
Center for Genetics & Pharmacology

701 Ellicott Street
Buffalo NY, 14203

Hosted by: Lei Wei, PhD,
Associate Professor of Oncology
Co-Director, Bioinformatics Core Resource
Department of Biostatistics and Bioinformatics
Roswell Park Comprehensive Cancer Center

Register today

Ralph DeBerardinis, MD, UT Southwestern, Distinguished Lecture Series 2023
Professor of Oncology
Children’s Medical Center Research Institute at UT Southwestern
Dallas, Texas

Thursday, December 14, 2023, 3:00 p.m.

Hosted by: Subhamoy Dasgupta, PhD,
Associate Professor of Oncology, Cell Stress Biology
Department of Cell Stress Biology
Roswell Park Comprehensive Cancer Center